FDA Approves New Drug Combination Treatment for CCP Virus

The U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Nov. 17, 2020, Jacquelyn Martin/AP Photo

The Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for a promising new drug cocktail for hospitalized CCP virus patients.

The treatment involves combining remdesivir with the anti-inflammatory oral drug baricitinib for patients 2 years of age or older who need supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), according to the FDA.